IL13RA2 and glioblastoma: In preclinical tests, CAR T cells designed to target IL13Rα2 produced copious amounts of immunostimulatory cytokines in presence of IL13Rα2-expressing GBM tumor cell lines as well as patient tumor cells indicating the high specificity.